- Home
- CAES vs EBS Comparison
CAES vs EBS Comparison
Compare CAES & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAES | EBS |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.4M | 312.8M |
| IPO Year | 2026 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CAES | EBS |
|---|---|---|
| Price | $10.06 | $6.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 16.3K | ★ 1.1M |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.05 | $4.36 |
| 52 Week High | $10.12 | $14.06 |
Technical Indicators
Market Signals| Indicator | CAES | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | N/A |
| Support Level | $10.06 | N/A |
| Resistance Level | $10.09 | N/A |
| Average True Range (ATR) | 0.01 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 37.50 | 0.00 |
Price Performance
Historical ComparisonAbout CAES Cantor Equity Partners VII Inc. Class A Ordinary Shares
Cantor Equity Partners VII Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.